

## Putting Purpose into Policy

A Clinical Nurse Specialist-Led Initiative to Reduce Variations in Chemotherapy Practice

Carrie Marvill, MSN, RN, AOCNS  
Clinical Nurse Education Specialist  
Pennsylvania Hospital – Penn Medicine, Philadelphia, PA

NACNS 2018 Annual Conference  
March 1, 2018



---

---

---

---

---

---

---

---

## Learning Objectives

- ◆ Demonstrate project alignment with strategic imperatives
- ◆ Identify strategies to standardize chemotherapy administration practices across the care continuum
- ◆ Examine the process of policy review at the system level



2

---

---

---

---

---

---

---

---

## Identified Gaps

- ◆ Different electronic medical records are utilized in the inpatient and ambulatory clinical areas
- ◆ Separate chemotherapy policies for pharmacy, inpatient, and ambulatory nursing
- ◆ Nursing policies address areas of practice for providers, pharmacists, and nurses, yet, the policy is written and updated solely by nursing
- ◆ Policy variations from that of other health system entities



3

---

---

---

---


---

---

---

---

## Alignment with Professional Models



Organizational Framework for Clinical Nurse Specialist Core Competencies

---

---

---

---

---

---


---

---

---

---

## Timeline of Project




---

---

---

---

---

---

---

---

---

---

## Assessment of Current State

- Inpatient and Ambulatory on two different Electronic Medical Records (EMR)
- 8+ hospital policies addressing chemotherapy
- Policies not adherent to best practices
- Confusion among chemotherapy providers
- Minimal safety event reports entered related to chemotherapy
- Delays in Care for Patients

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

### Identification of Variation in Policy

Heading	Final Injection Policy "Chemotherapy Drug"	Final Outpatient Policy	Final Pharmacy Policy "Order for Chemotherapy Agent"	HQ/OP/DP Policy "Chemotherapy Medication Order"
<b>Policy Statement</b>	Chemotherapy agents will be prepared, dispensed, administered and monitored according to standards developed by the Oncology Nurse Society and approved by the Pharmacy and Therapeutics Committee.	Chemotherapy agents will be prepared, dispensed, administered and monitored according to standards developed by the Oncology Nurse Society and approved by the Pharmacy and Therapeutics Committee.	This policy applies to the Pharmacy Department and those parts of the Central Pharmacy of the University of Pennsylvania (COPU) who practice as a part of outpatient medicine, operating under the Pharmacy and Therapeutics Committee (PTC) and (PTC) (i) those practices and those that are off-campus practices or departments of PAU and operating under its license (as an ambulatory care practice).	Chemotherapy agents will be prepared, dispensed, administered and monitored according to standards developed by the Pharmacy and Therapeutics Committee and approved by the Pharmacy and Therapeutics Committee.
<b>Reference</b>			Other related policies by Penn including: e.g. Surgery Center of Penn and Emancipatory Center of Penn, (i) practice entities that have taken in property owned or leased by Penn and (ii) personnel that provide contracted clinical services to Penn, and (iii) personnel that provide contracted clinical services to other patients.	
<b>Purpose</b>	To provide safe chemotherapy and that minimizes medication errors and avoid medication adverse events to patients through accurate and consistent:	To provide safe chemotherapy use that minimizes medication errors and avoid medication adverse events to patients through accurate and consistent:	The purpose of this policy is to ensure patient safety by providing clear guidance on ordering, dispensing, and administering chemotherapy. This policy applies to chemotherapy ordering and administration in both inpatient and outpatient settings.	The purpose of this policy is to provide for safe medication use that minimizes medication mistakes and avoid medication adverse drug events in patients through accurate and appropriate:
<b>Reference</b>	A. Drug prescribing B. Drug administration C. Chemotherapy verification procedure D. Environmental safety issues	A. Drug prescribing B. Drug administration C. Chemotherapy verification procedure D. Environmental safety issues		A. Drug prescribing B. Drug dispensation C. Drug administration D. Drug monitoring E. Pharmaceutical safety control

UPHS Chemotherapy Policy Comparison Chart 2

Penn Medicine 8

---

---

---

---

---

---

---

---

---

---

### Safety Event Themes

Theme	%
Other error	65%
Delay in administration	41%
Improper safe handling	41%
No consent on file	35%
Unauthorized administration	35%
Medications not given as ordered	35%
Order entry error	35%
No Attending Signature	29%

Penn Medicine 9

---

---

---

---

---

---

---

---

---

---

## Chemotherapy Administration Standards



---

---

---

---

---

---

---

---

---

---

## Multiple Revisions

MED-CH-29 Chemo Policy revised 6.11.2017 with color coding	6/16/2017 1:51 PM	Microsoft Word D.
MED-CH-29 Chemo Policy revised 6.11.2017	6/15/2017 11:11 AM	Microsoft Word D.
MED-CH-29 Chemo Policy revised 6.16.2017 outline	6/16/2017 9:42 AM	Microsoft Word D.
MED-CH-29 Chemo Policy revised 6.16.2017	6/16/2017 9:51 AM	Microsoft Word D.
MED-CH-29 Chemo Policy revised 6.2017	6/9/2017 1:24 PM	Microsoft Word D.
MED-CH-29 Chemo Policy revised 6.2017	6/9/2017 1:25 PM	Adobe Acrobat D.
MED-CH-29 Chemo Policy TRACK CHANGES 12.2016	2/16/2017 3:33 PM	Microsoft Word R.
MED-CH-29 Policy revised 2.8.2017	3/7/2017 3:01 PM	Microsoft Word D.
MED-CH-29 Policy revised 3.8.2017	3/8/2017 2:52 PM	Microsoft Word D.
MED-CH-29 Policy revised 3.8.2017	3/23/2017 11:23 AM	Microsoft Word D.
MED-CH-29 Policy revised 4.8.2017	5/9/2017 4:49 PM	Microsoft Word D.
MED-CH-29 Policy revised 5.9.2017	5/20/2017 8:39 AM	Microsoft Word D.
MED-CH-29 Policy revised 6.2.2017	6/8/2017 7:53 AM	Microsoft Word D.
MED-CH-29 Policy revised 6.16.2017 SK 061017_Edits for Carrie062017	6/9/2017 9:56 AM	Microsoft Word D.
MMM Chemotherapy Use Administrative Policy 6.16.2017_SK 061017_Edits for Carrie062017	6/9/2017 11:01 AM	Microsoft Word R.
MMM Chemotherapy Use Administrative Policy 6.16.2017	6/21/2017 7:55 AM	Microsoft Word R.
MMM Chemotherapy Use Administrative Policy 6.30.2017	7/14/2017 10:17 AM	Microsoft Word R.
MMM Chemotherapy Use Administrative Policy 7.14.2017	7/19/2017 9:42 AM	Microsoft Word D.
MMM Chemotherapy Use Administrative Policy 7.20.2017	7/21/2017 8:45 AM	Microsoft Word D.
MMM Chemotherapy Use Administrative Policy 8.01.2017	8/2/2017 9:59 AM	Microsoft Word D.
MMM Chemotherapy Use Administrative Policy 8.11.2017	8/15/2017 2:58 PM	Microsoft Word D.
MMM Chemotherapy Use Administrative Policy 8.15.2017	9/13/2017 9:44 AM	Microsoft Word D.
MMM Chemotherapy Use Administrative Policy 8.11.2017	10/30/2017 7:13 AM	Microsoft Word D.

---

---

---

---

---

---

---

---

---

---

## Policy Updates

- Converted to Administrative Policy
- Defined "Antineoplastic Agent"
- Consent required for all drugs as defined
- Clarified prescribing/ordering as determined by security limits in EMR in both inpatient and outpatient settings
- Standardized Body Surface Area formula
- Addition of Emergent Chemotherapy Activation Procedure & Orderset
- Process for non-formulary chemotherapy orders
- Administration of oral chemotherapy
- Chemotherapy Certification Procedure

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

- ### Communication Plan
- **Chemotherapy Biotherapy Oversight Committee**
    - November 2016 - June 2017 and quarterly review ongoing
  - **Nursing Practice Committee**
  - **Pharmacy and Therapeutics**
  - **Administrative Manual Committee**
  - **Hematology/Oncology Stakeholders**
  - **Non-Oncology Stakeholders – IR, OR, ED, etc**
  - **Nursing Education**
  - **Nurse Executive Board**
  - **Inpatient and Ambulatory Nursing**
- Penn Medicine 14

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---